Mergers and acquisitions – Page 11
-
Business
US chemical maker Platform expands with Alent purchase
Platform Specialty Products plans to enlarge its scope and reach by acquiring British chemicals firm Alent for $2.1bn
-
Business
Celgene backs immunotherapy with Juno collaboration
$1bn investment in 10-year CAR-T cell partnership for cancer treatments
-
Business
Thermo Fisher to buy Alfa Aesar chemical supplies
Research chemicals business no longer a strategic fit for owner Johnson Matthey
-
FeaturePharma queues up for checkpoint inhibitor collaborations
Combinations of different firms’ drugs seek to reap immuno-oncology’s benefits
-
Business
Allergan to buy Kythera Biopharma for $2.1bn
Acquisition strengthens firm’s position in cosmetic treatments with only drug approved for a ‘double chin’
-
Business
Vertex nabs rights to cystic fibrosis molecules
Deal with Parion, worth up to $1bn, gives firm worldwide rights to investigational treatments that complement Vertex’s existing cystic fibrosis drugs
-
Business
Opko deepens diagnostics with $1.5bn lab buyout
Taking over clinical diagnostics service provider BioReference Laboratories gives Opko a bigger avenue to distribute and market its diagnostic tests
-
Business
OM Group to be sold and split
Apollo Global Management will buy the firm for $1bn, then sell electronic materials business to Platform Specialty Products
-
Business
Endo to buy Par as generics consolidation continues
$8bn deal follows trend as drugmakers aim for economies of scale
-
Business$13.8bn Danaher bid wins Pall auction
Mega-merger follows consolidation trend in lab equipment supply sector, but analysts suggest this is yet to impact pricing competition
-
Business
Alexion to buy Synageva for rare disease drugs
$8.4bn deal gives firm access to enzyme drug currently under review with US and EU regulators
-
BusinessMerger creates biggest supplier of unlicensed drugs
Clinigen will buy Idis to consolidate different routes by which doctors can access medicines that are unavailable locally
-
BusinessGenerics firms in three-way takeover battle
Mylan is chasing Perrigo, while fending off advances from Teva
-
Business
Daiichi Sankyo steps out after Sun-Ranbaxy merger
Ranbaxy’s Japanese owner has sold off its stake in the merged company, but will retain its business partnership
-
Business
Generics giant Mylan offers $30 billion for Perrigo
Mylan makes ambitious takeover offer just weeks after Abbott aquisition closes
-
Business
BMS invests in gene therapy
Bristol-Myers Squibb makes $100 million deal with biotech uniQure
-
Business
Horizon to acquire orphan drugs in $1.1bn Hyperion takeover
Horizon will buy Hyperion and add new drugs to its rare disease portfolio
-
Business
Dow sells off chlorine assets in $5bn deal
US chemical giant disposes of unwanted operations in tax-free deal
-
Business
Sun Pharma snares Ranbaxy in $4bn deal
Acquisition makes Sun biggest drug firm in India and fifth largest generics producer in the world
-
Business
Teva buys Auspex Pharmaceuticals for $3.2bn
Generics giant will add late stage Huntingdon’s drug to CNS portfolio